Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (3): 287-289.DOI: 10.3969/j.issn.1673-8640.2020.03.021
Previous Articles Next Articles
Received:2019-04-08
Online:2020-03-30
Published:2020-04-17
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.03.021
| [1] | CABAGNOLS X,CAYUELA J M,VAINCHENKER W.A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm[J]. N Engl J Med,2015,372(7):688-690. |
| [2] | LOGHAVI S,PEMMARAJU N,KANAGAL-SHAMANNA R,et al.Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1[J]. Blood,2015,125(21):3360-3363. |
| [3] | BONZHEIM I,MANKEL B,KLAPTHOR P,et al.CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation[J]. Blood,2015,125(14):2309-2311. |
| [4] | DIAMOND J M,DE ALMEIDA A M,BELO H J,et al. CALR-mutated primary myelofibrosis evolving to chronic myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene[J]. Ann Hematol,2016,95(12):2101-2104. |
| [5] | SEGHATOLESLAMI M,KETABCHI N,ORDO A,et al.Coexistence of p190 BCR/ABL transcript and CALR 52-bp deletion in chronic myeloid leukemia blast crisis:a case report[J]. Mediterr J Hematol Infect Dis,2016,8(1):e2016002. |
| [6] | DOGLIOTTI I,FAVA C,SERRA A,et al.CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report[J]. Stem Cell Investig,2017,4:57. |
| [7] | KANDARPA M,WU Y M,ROBINSON D,et al.Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis[J]. Am J Hematol,2017,92(6):555-561. |
| [8] | BLOUET A,ROUSSELET M,LE BRIS Y,et al.Imatinib treatment of chronic myeloid leukemia reveals a preexisting CALR-mutated essential thrombocythemia[J]. Hemasphere,2018,2(1):e29. |
| [9] | KLAIRMONT M M,CHENG J,SCHWARTZBERG L,et al.Chronic myeloid leukemia,BCR-ABL1-positive with CALR and MPL mutations[J]. Int J Lab Hematol,2018,40(3):e41-e42. |
| [10] | LEWANDOWSKI K,GNIOT M,WOJTASZEWSKA M,et al.Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors[J]. Int J Lab Hematol,2018,40(3):366-371. |
| [11] | XIA D,HSI E D,CIN P D,et al.Composite chronic myeloid leukemia and essential thrombocythemia with BCR-ABL1 fusion and CALR mutation[J]. Am J Hematol,2019,94(4):504-505. |
| [12] | MERLINSKY T R,LEVINE R L,PRONIER E.Unfolding the role of calreticulin in myeloproliferative neoplasm pathogenesis[J]. Clin Cancer Res,2019,25(10):2956-2962. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
